The third supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. A compendium of resources for professionals who work with parents involved with child welfare.

This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory discusses the epidemiology of the mental health symptoms and conditions of Long COVID, provides evidence-based resources for the treatment of those conditions, and offers possible resources.

This TIP supports learning about the key aspects, functions, and uses of Peer Support Services (PSS) in recovery from problematic substance use, which will help providers, supervisors, and administrators in SUD treatment programs better understand and respond to these changes.

An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.

Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.